Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT6026 in Moderate to Severe Atopic Dermatitis
NCT06094179Phase 2Active, not recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BAT6026 in atopic dermatitis (AD) (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Tolerance at 1 week, Vital signs at 1 week and 4 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
BAT6026
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06094179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094179.